Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* APC/Fire? 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation.?Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
13. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed

1. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
2. Limon JJ et al. 2019. Cell host & microbe. 25(3):377-388 . PubMed
3. Cheng G, et al. 2021. iScience. 24:102673. PubMed
4. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
5. Shiao SL, et al. 2021. Cancer Cell. :. PubMed
6. Li A, et al. 2020. J Virol. 94:00:00. PubMed
7. Abbott RK, et al. 2018. Immunity. 48:133. PubMed
8. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
9. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
10. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
11. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
12. Deets KA, et al. 2021. Elife. 10:. PubMed

Majority of thymocytes, T cell subset

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.